MAGE-3 (114-122)

MAGE-3 (114-122) is a synthetic peptide corresponding to amino acid residues 114 to 122 of the melanoma-associated antigen 3 (MAGE-3) protein. As a member of the MAGE family, this peptide represents a well-characterized epitope derived from a tumor-associated antigen that is expressed in various malignancies and minimally in normal tissues, except for testicular germ cells. Its defined sequence and immunogenic properties make it highly relevant for immunological research, particularly in the context of tumor antigen recognition, T cell epitope mapping, and the study of antigen processing and presentation. MAGE-3 (114-122) is frequently utilized in experimental systems to investigate the molecular mechanisms underpinning adaptive immune responses to cancer antigens.

Epitope mapping: The peptide is widely used in epitope mapping studies to delineate the specific regions of MAGE-3 recognized by cytotoxic T lymphocytes (CTLs). By providing a defined sequence, researchers can assess T cell receptor specificity and identify minimal antigenic determinants required for immune recognition. Such mapping is essential for understanding the immunodominance hierarchies within tumor antigens and for the rational design of peptide-based immunological assays.

Antigen presentation studies: MAGE-3 (114-122) serves as a valuable tool for investigating the processing and presentation of tumor antigens by major histocompatibility complex (MHC) molecules. In vitro loading of this peptide onto antigen-presenting cells enables the study of MHC class I-restricted presentation, facilitating the dissection of cellular mechanisms involved in peptide loading, stability, and surface expression. These studies provide insights into the factors influencing antigen availability to T cells within the tumor microenvironment.

T cell activation assays: The peptide is instrumental in functional assays designed to evaluate the activation and cytolytic potential of antigen-specific T cells. When presented by appropriate MHC molecules, MAGE-3 (114-122) can stimulate CTLs in vitro, allowing researchers to quantify cytokine release, proliferation, and cytotoxic activity. Such assays are crucial for assessing the efficacy of T cell responses in preclinical models and for optimizing protocols in adoptive cell therapy research.

Peptide-based assay development: Due to its well-defined sequence and immunological relevance, MAGE-3 (114-122) is commonly incorporated into the development of peptide-based ELISPOT, flow cytometry, and tetramer staining assays. These platforms leverage the peptide as a probe to detect and enumerate antigen-specific T cells in heterogeneous populations. The use of this peptide in such assays enhances the sensitivity and specificity of immune monitoring in experimental oncology and vaccine development settings.

Peptide synthesis and structural studies: The defined nature of MAGE-3 (114-122) makes it a model substrate for peptide synthesis optimization and structure-activity relationship investigations. Researchers employ this peptide to evaluate synthetic methodologies, study peptide-MHC binding affinities, and analyze conformational properties using biophysical techniques. These applications contribute to the broader understanding of peptide chemistry and the rational design of immunogenic epitopes for research use.

1. Crystal Structure of BamB from Pseudomonas aeruginosa and Functional Evaluation of Its Conserved Structural Features

2. Peptides as Active Ingredients: A Challenge for Cosmeceutical Industry

3. Adipose tissue is a key organ for the beneficial effects of GLP-2 metabolic function

4. Sex differences in oxidative stress level and antioxidative enzymes expression and activity in obese pre-diabetic elderly rats treated with metformin or liraglutide

5. cRGD-functionalized, DOX-conjugated, and 64Cu-labeled superparamagnetic iron oxide nanoparticles for targeted anticancer drug delivery and PET/MR imaging